{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:26:17Z","timestamp":1764433577865,"version":"3.41.2"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and severe cutaneous adverse drug reactions (SCARs) with high mortality. Antibiotics are the most frequent causative agents related to DRESS. However, it is rarely reported in cephalosporins, especially for ceftazidime. Here, we reported a case of ceftazidime-induced DRESS with HLA genotypic polymorphism as a risk factor. A 58-year-old woman with connective tissue disease was intravenously infused with ceftazidime for the treatment of pneumonia and intestinal infection, followed by the presence of fever, rash, and hematologic and hepatic laboratory abnormalities. DRESS was diagnosed and the positive polymorphism in HLA-B*15:02 was found. Our case illustrated the necessity to clarify the patho-mechanism and the use of pretreatment HLA analysis to prevent ceftazidime-related DRESS may be a valuable option soon.<\/jats:p>","DOI":"10.3389\/fphar.2024.1403390","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T05:02:25Z","timestamp":1723438945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by ceftazidime in a connective tissue disease (CTD) patient"],"prefix":"10.3389","volume":"15","author":[{"given":"Rui","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziran","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11926-017-0626-z","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and the rheumatologist","volume":"19","author":"Adwan","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/jdv.15986","article-title":"Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions","volume":"34","author":"B\u00e9rot","year":"2020","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B3","first-page":"331","article-title":"Cross-reactivity and tolerability of cephalosporins in patients with cell-mediated allergy to penicillins","volume":"24","author":"Buonomo","year":"2014","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/ijms18061243","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","volume":"18","author":"Cho","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"B7","article-title":"Carbamazepine therapy and HLA genotype","volume-title":"Medical genetics summaries","author":"Dean","year":"2012"},{"volume-title":"DRESS syndrome: drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome (DHS)","year":"2018","author":"DeClerck","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jbspin.2013.05.002","article-title":"DRESS syndrome","volume":"81","author":"Descamps","year":"2014","journal-title":"Jt. Bone Spine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br. J. Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/ph14111077","article-title":"A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine","volume":"14","author":"Kloypan","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/bcp.15419","article-title":"Cefotaxime-induced drug reaction with eosinophilia and systemic symptom in a child with cross-reactivity to other cephalosporins and cosensitization to teicoplanin","volume":"89","author":"Mansour","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.revmed.2022.04.018","article-title":"HLA-B58.01 and allopurinol hypersensitivity renal vasculitis in a Chinese patient","volume":"43","author":"Mariette","year":"2022","journal-title":"Rev. Med. Interne"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9710376","DOI":"10.1155\/2022\/9710376","article-title":"Human leukocyte antigen (HLA) system: genetics and association with bacterial and viral infections","volume":"2022","author":"Medhasi","year":"2022","journal-title":"J. Immunol. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1345\/aph.18383","article-title":"Lamotrigine overdose presenting as anticonvulsant hypersensitivity syndrome","volume":"33","author":"Mylonakis","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"volume-title":"LiverTox: clinical and research information on drug-induced liver Injury","year":"2012","key":"B18"},{"key":"B19","doi-asserted-by":"publisher","first-page":"969912","DOI":"10.3389\/fimmu.2022.969912","article-title":"Case report: drug rash with eosinophilia and systemic symptoms syndrome in a patient with anti-interferon-\u03b3 autoantibody-associated immunodeficiency","volume":"13","author":"Nie","year":"2022","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jaip.2013.04.001","article-title":"Ceftazidime-induced drug reaction with eosinophilia and systemic symptoms (DRESS) complicated by hemophagocytic lymphohistiocytosis","volume":"1","author":"Picard","year":"2013","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/jdv.13796","article-title":"Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics","volume":"31","author":"Pinho","year":"2017","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jaci.2011.12.995","article-title":"Diagnosing nonimmediate reactions to cephalosporins","volume":"129","author":"Romano","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","article-title":"Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles","volume":"81","author":"Saper","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/idoj.idoj_196_21","article-title":"RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DiHS): a comparative analysis","volume":"13","author":"Sasidharanpillai","year":"2022","journal-title":"Indian Dermatol Online J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00228-020-03005-9","article-title":"Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review","volume":"77","author":"Sharifzadeh","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14740338.2017.1270940","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management","volume":"16","author":"Shiohara","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/pds.4774","article-title":"Variation of clinical manifestations according to culprit drugs in DRESS syndrome","volume":"28","author":"Sim","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5935\/0004-2749.20160055","article-title":"DRESS syndrome in ophthalmic patients","volume":"79","author":"Sousa","year":"2016","journal-title":"Arq. Bras. Oftalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamadermatol.2013.6698","article-title":"Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features","volume":"150","author":"Tetart","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"954596","DOI":"10.3389\/fphar.2022.954596","article-title":"Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/pgs.14.69","article-title":"HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population","volume":"15","author":"Yang","year":"2014","journal-title":"Pharmacogenomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403390\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T05:02:30Z","timestamp":1723438950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403390\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":33,"alternative-id":["10.3389\/fphar.2024.1403390"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1403390","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"article-number":"1403390"}}